DCM
BIOL

Dialectic Capital Management’s Biolase, Inc. BIOL Stock Holding History

Dialectic Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7
Closed -$288K – 226
2013
Q2 		$288K Buy
+7
New +$391K 0.04% 173

Other funds holding BIOL

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TA
Teton Advisors Rye, New York $173M AUM 77.13% 1-Year Est. Return

Dialectic Capital Management's BIOL Position: Q3 2013 in Review

Dialectic Capital Management sold out of Biolase, Inc. (BIOL) in Q3 2013, closing a stake of 7 shares — an estimated $288K sold.

Dialectic Capital Management first reported a position in BIOL in Q2 2013 and held it in 1 quarter. The position peaked at $288K in Q2 2013. 44 funds tracked by Wall St. Rank hold BIOL as of Q3 2013.

  • Dialectic Capital Management reported no remaining Biolase, Inc. position as of Q3 2013 after selling out during the quarter.
  • Dialectic Capital Management sold 7 Biolase, Inc. shares in Q3 2013, an estimated $288K.
  • Dialectic Capital Management first reported a position in Biolase, Inc. in Q2 2013 and held it in 1 quarter.
  • Dialectic Capital Management's Biolase, Inc. position peaked at $288K in Q2 2013.
  • 44 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2013.

Based on Dialectic Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.